Cargando…
A Review of Biomarkers for Alzheimer’s Disease in Down Syndrome
Down syndrome (Trisomy 21; DS) is a unique disease known to be associated with early-onset Alzheimer’s disease (AD). The initial presentation of AD in DS is usually difficult to recognize, owing to the underlying intellectual disabilities. Using biomarkers as a prediction tool for detecting AD in at...
Autores principales: | Lee, Ni-Chung, Chien, Yin-Hsiu, Hwu, Wuh-Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520817/ https://www.ncbi.nlm.nih.gov/pubmed/28733957 http://dx.doi.org/10.1007/s40120-017-0071-y |
Ejemplares similares
-
A review of treatment of Pompe disease in infants
por: Chien, Yin-Hsiu, et al.
Publicado: (2007) -
Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer’s Disease
por: Lee, Ni-Chung, et al.
Publicado: (2017) -
Development of Newborn Screening for Pompe Disease
por: Hwu, Wuh-Liang, et al.
Publicado: (2020) -
The Timely Needs for Infantile Onset Pompe Disease Newborn Screening—Practice in Taiwan
por: Chiang, Shu-Chuan, et al.
Publicado: (2020) -
Myostatin and Insulin-Like Growth Factor I: Potential Therapeutic Biomarkers for Pompe Disease
por: Chien, Yin-Hsiu, et al.
Publicado: (2013)